STERIS (Ireland) (STE) - 11.72% Below 52-Week High: Buy or Wait?

Stock Details

STERIS plc (Ireland) (STE), a prominent company in the healthcare sector within the medical devices industry, is based in United States and primarily trades on the NYQ.Currently, the stock is trading at $237.85. Over the past 52 weeks, it has ranged between $195.14 and $269.44. This places the current price at 88.3% of its 52-week high and 21.9% above its 52-week low. Recent trading volume was recorded at 302,216. The International Securities Identification Number (ISIN) for this stock is US8589121081.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

28.80

Above market average

Forward P/E

18.70

Earnings expected to grow

PEG Ratio

1.90

Reasonably valued

Price to Book

3.11

EV/EBITDA

14.99

EPS (TTM)

$7.93

Price to Sales

3.75

Beta

0.92

Less volatile than market

Q:How is STE valued relative to its earnings and growth?

STERIS plc (Ireland) trades at a P/E ratio of 28.80, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 18.70 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.90 indicates reasonable value when growth is considered.

Q:What is STE's risk profile compared to the market?

With a beta of 0.92, STERIS plc (Ireland) is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.11 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

13.18%

Operating Margin

20.04%

EBITDA

$1.60B

Return on Equity

11.37%

Return on Assets

6.65%

Revenue Growth (YoY)

7.30%

Earnings Growth (YoY)

52.20%

Q:How profitable and efficient is STE's business model?

STERIS plc (Ireland) achieves a profit margin of 13.18%, meaning it retains $13.18 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 20.04% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 11.37% and ROA at 6.65%, the company achieves moderate returns on invested capital.

Q:What are STE's recent growth trends?

STERIS plc (Ireland)'s revenue grew by 7.30% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 52.20% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against Medical Devices industry averages for proper context.

Dividend Information

Dividend Per Share

$2.58

Dividend Yield

1.13%

Ex-Dividend Date

Sep 4, 2026

Dividend Date

Jun 26, 2026

Q:What dividend income can investors expect from STE?

STERIS plc (Ireland) offers a dividend yield of 1.13%, paying $2.58 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Sep 4, 2026.

Q:How reliable is STE's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - STERIS plc (Ireland) pays $2.58 per share in dividends against earnings of $7.93 per share, resulting in a payout ratio of 32.53%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for Jun 26, 2026.

Company Size & Market

Market Cap

$22.3B

Revenue (TTM)

$5.94B

Revenue/Share (TTM)

$60.45

Shares Outstanding

97.46M

Book Value/Share

$73.45

Asset Type

EQUITY

Q:What is STE's market capitalization and position?

STERIS plc (Ireland) has a market capitalization of $22.3B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 97.46M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Medical Devices industry, it competes with other firms in this sector.

Q:How does STE's price compare to its book value?

STERIS plc (Ireland)'s book value per share is $73.45, while the current stock price is $237.85, resulting in a price-to-book (P/B) ratio of 3.24. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$255.38

7.37% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for STE?

9 analysts cover STE with 67% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $255.38 implies 7.4% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on STE?

Current analyst recommendations:3 Strong Buy, 3 Buy, 2 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 2, 2026, 02:50 AM

STERIS plc (Ireland) (STE) Stock